72 related articles for article (PubMed ID: 3266874)
1. [An experimental study on the in vivo induction of lymphokine activated killer (LAK) cells by the continuous infusion of interleukin 2 (IL-2) through the splenic artery].
Ohnishi H
Nihon Gan Chiryo Gakkai Shi; 1988 Dec; 23(11):2785-93. PubMed ID: 3266874
[No Abstract] [Full Text] [Related]
2. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
3. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M
Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099
[TBL] [Abstract][Full Text] [Related]
5. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
6. Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.
Hoyer M; Meineke T; Lewis W; Zwilling B; Rinehart J
Cancer Res; 1986 Jun; 46(6):2834-8. PubMed ID: 2421884
[TBL] [Abstract][Full Text] [Related]
7. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2.
Zwilling BS; Aldrich WA; Rinehart JJ
Cancer Res; 1986 Nov; 46(11):5667-70. PubMed ID: 3489527
[TBL] [Abstract][Full Text] [Related]
9. Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery.
Ohnishi H; Okuno K; Yasutomi M
Cancer Biother; 1993; 8(3):213-22. PubMed ID: 7804361
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
12. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
Papa MZ; Vetto JT; Ettinghausen SE; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5618-23. PubMed ID: 3489525
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells.
Brubaker JO; Chong KT; Welsh RM
J Immunol; 1991 Aug; 147(4):1439-44. PubMed ID: 1869833
[TBL] [Abstract][Full Text] [Related]
15. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
17. [Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
Kimura H; Yamaguchi Y; Obata S; Yusa T; Sekine Y
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2401-4. PubMed ID: 3137876
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
19. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
20. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
